{"gene":"S100B","run_date":"2026-06-10T07:46:28","timeline":{"discoveries":[{"year":2007,"finding":"X-ray crystal structure of human Ca2+-loaded S100B at 1.9 Å resolution revealed an octameric architecture of four homodimeric units arranged as two tetramers. Tetrameric S100B binds RAGE with higher affinity than dimeric S100B, and analytical ultracentrifugation showed the tetramer binds two RAGE molecules via the V-domain. Tetrameric S100B caused stronger activation of cell growth and survival than dimeric S100B.","method":"X-ray crystallography, size-exclusion chromatography, analytical ultracentrifugation, cell growth/survival assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with biophysical binding studies and functional cell assays in a single rigorous study","pmids":["17660747"],"is_preprint":false},{"year":1997,"finding":"High concentrations of S100beta treatment of astrocytes activates inducible nitric oxide synthase (iNOS) and causes NO release; in astrocyte-neuron co-cultures, this S100beta-induced NO from astrocytes caused neuronal cell death (both necrosis and apoptosis). Neuronal death was blocked by a specific NOS inhibitor, establishing that S100B acts through iNOS/NO in astrocytes to cause neurotoxicity.","method":"Astrocyte-neuron co-culture, NOS inhibitor pharmacology, cell death assays (propidium iodide, TUNEL, apoptosis morphology)","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean pharmacological rescue (NOS inhibitor blocks death), replicated with multiple readouts of cell death, consistent with independent studies","pmids":["9375660"],"is_preprint":false},{"year":2018,"finding":"S100B suppresses Aβ42 aggregation in a calcium-dependent manner. NMR experiments showed that the interaction occurs at a promiscuous peptide-binding region within the interfacial cleft of the S100B homodimer; calcium binding to S100B favors interaction with monomeric Aβ42, possibly inducing an α-helical conformer that locks aggregation. S100B delays onset of Aβ42 aggregation by inhibiting primary nucleation and inhibits fibril surface-catalyzed secondary nucleation by binding oligomers and fibrils. S100B protected cells from Aβ42-mediated toxicity.","method":"NMR spectroscopy, thioflavin-T aggregation kinetics assays, cell viability/apoptosis assays","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1 / Strong — structural (NMR) plus in vitro reconstitution of aggregation kinetics plus cell-based functional validation in one study","pmids":["29963623"],"is_preprint":false},{"year":2010,"finding":"S100B forms a complex with p53 in malignant melanoma cells (C8146A). siRNA knockdown of S100B increased p53 protein, phosphorylated p53, and p53 target gene products (p21, PIDD) without changing p53 mRNA, and restored p53-dependent apoptosis via the Fas death receptor pathway (caspase 3/8 activation, PARP cleavage). Rescue with pifithrin-alpha (p53 inhibitor) reversed siRNA(S100B)-induced apoptosis, confirming the mechanism. Introduction of S100B into S100B-null cells reduced UV-induced apoptosis 7-fold.","method":"siRNA knockdown, Western blot, caspase activation assays, DNA laddering, flow cytometry, p53 inhibitor rescue","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (siRNA, gain-of-function, pharmacological rescue) in a single rigorous study with clean mechanistic dissection","pmids":["20587415"],"is_preprint":false},{"year":2006,"finding":"Extracellular S100B up-regulates cyclooxygenase-2 (COX-2) expression in microglia via RAGE in a concentration-dependent manner. Two independent downstream pathways were identified: a Cdc42-Rac1-JNK pathway and a Ras-Rac1-NF-κB pathway, both activated independently by S100B-RAGE signaling.","method":"Microglial cell culture, RAGE-dependent pharmacological inhibition, pathway inhibitor studies, Western blot, reporter assays","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway dissection with multiple inhibitors in a single lab; mechanistically detailed but not independently replicated","pmids":["17023559"],"is_preprint":false},{"year":1996,"finding":"Phosphoglucomutase was identified as an intracellular S100B (and S100A1) target protein. S100B bound phosphoglucomutase-Sepharose in a calcium-dependent manner (confirmed by reciprocal affinity chromatography and gel overlay). S100B stimulated phosphoglucomutase activity in a calcium-dependent manner, in contrast to S100A1 which inhibited it. Other calcium-binding proteins (calmodulin, troponin C, parvalbumin, α-lactalbumin) had no effect.","method":"Gel overlay, affinity chromatography (reciprocal), enzyme activity assay","journal":"Cell calcium","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro biochemical reconstitution with reciprocal affinity chromatography and functional enzyme assay; single lab","pmids":["8894274"],"is_preprint":false},{"year":2000,"finding":"S100A1 and S100B bind annexin VI in a Ca2+-dependent manner, forming heterotetramers in which an S100 homodimer crossbridges two copies of annexin VI. The C-terminal half of annexin VI (annexin VI-b), but not the N-terminal half (annexin VI-a), blocks the inhibitory effect of S100A1 and S100B on intermediate filament assembly. The C-terminal extension of S100B is not part of the surface implicated in annexin VI recognition. S100 proteins permeabilize membrane bilayers similarly to annexins.","method":"Co-immunoprecipitation/binding assays, intermediate filament assembly assay, liposome permeabilization and calcium influx assay","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays with domain mapping; single lab, in vitro","pmids":["11108963"],"is_preprint":false},{"year":2002,"finding":"Alpha1-adrenergic stimulation induces the S100B gene in cardiac myocytes specifically through the alpha1A-adrenergic receptor and the PKC signaling pathway. A basic promoter (spanning 162 bp upstream of the transcription initiation site) was identified as essential for transcription, along with positive and negative regulatory elements. TEF-1 transrepressed and RTEF-1 transactivated the maximal S100B promoter. This identifies S100B as a negative feedback regulator of alpha1-adrenergic/PKC-driven cardiac hypertrophy.","method":"Luciferase reporter assays with sequential 5'-deletion constructs, transfection of cardiac myocytes, adrenergic receptor agonists/antagonists","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic promoter deletion analysis with multiple regulatory element identifications; single lab","pmids":["12388300"],"is_preprint":false},{"year":1998,"finding":"Forced expression of S100B in neonatal rat cardiac myocyte cultures and high-level expression in transgenic mouse hearts inhibits cardiac hypertrophy and associated phenotype by modulating protein kinase C-dependent pathways. S100B is induced after myocardial infarction and acts as a negative feedback regulator limiting cardiomyocyte hypertrophy.","method":"Forced gene expression in primary myocyte cultures, transgenic mouse model, PKC pathway analysis","journal":"Canadian journal of applied physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro overexpression plus transgenic mouse validation; single lab, limited mechanistic detail in abstract","pmids":["9677434"],"is_preprint":false},{"year":2010,"finding":"S100B induces apoptosis in cardiomyocytes via an extracellular mechanism by engaging RAGE and activating ERK1/2 and p53 signaling. Knocking out S100B augmented hypertrophy, decreased apoptosis, and preserved cardiac function following myocardial infarction.","method":"S100B knockout mouse model, exogenous S100B treatment, Western blot for ERK1/2 and p53 signaling","journal":"Amino acids","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO model with defined phenotypic and signaling readout; single lab review citing prior experimental work","pmids":["20204434"],"is_preprint":false},{"year":1994,"finding":"Transgenic mice expressing 2-fold and 7-fold elevated S100B show concomitant astrocytosis and axonal sprouting in the hippocampus (elevated GFAP, neurofilament L, phosphorylated NF-H/M, beta-tubulin), demonstrating that elevated S100B in vivo promotes both astrocyte morphological changes and neurite proliferation, particularly in the dentate gyrus.","method":"S100B transgenic mouse model, Western blot, immunocytochemistry","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo transgenic gain-of-function with quantitative protein markers and histology; single lab","pmids":["8202493"],"is_preprint":false},{"year":2019,"finding":"Calsyntenin 3β (a novel ER protein in thermogenic adipocytes) promotes ER localization and secretion of S100B from brown adipocytes despite S100B lacking a signal peptide. S100B stimulates neurite outgrowth from sympathetic neurons in vitro. S100B deficiency phenocopies calsyntenin 3β deficiency (reduced sympathetic innervation of adipose tissue), and forced S100B expression in brown adipocytes rescues the innervation defect caused by calsyntenin 3β ablation.","method":"Genetic loss/gain-of-function in adipocytes, in vitro neurite outgrowth assay, rescue experiments with forced S100B expression","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (KO phenocopy + rescue), in vitro functional assay, multiple orthogonal approaches in high-impact study","pmids":["31043739"],"is_preprint":false},{"year":2023,"finding":"YAP/TAZ in adipocytes transcriptionally repress S100B expression by competing with C/EBPβ for binding to the zinc finger-2 domain of PRDM16, thereby suppressing PRDM16-C/EBPβ-mediated S100b transcription. Adrenergic stimulation phosphorylates and inactivates YAP/TAZ, releasing this repression to allow S100B expression and sympathetic innervation of beige fat.","method":"Adipocyte-specific Yap/Taz knockout, AAV-S100B overexpression, co-immunoprecipitation of YAP/TAZ-PRDM16-C/EBPβ interactions, transcriptional reporter assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO plus rescue, molecular mechanism defined by protein-protein interaction studies and transcriptional assays, multiple orthogonal methods","pmids":["37925548"],"is_preprint":false},{"year":2014,"finding":"SOX10 transcription factor transactivates the S100B promoter in Schwann cells through three core response elements in the S100B promoter and intron 1 containing SOX motifs. SOX10 overexpression dramatically induces S100B expression; SOX10 knockdown suppresses S100B. Knockdown of either SOX10 or S100B enhances Schwann cell proliferation, and S100B knockdown impairs myelination in dorsal root ganglion co-cultures.","method":"SOX10 overexpression/shRNA knockdown, S100B shRNA knockdown, luciferase reporter with SOX motif mapping, DRG myelination assay","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — transcriptional mechanism defined by promoter mapping plus gain- and loss-of-function with functional myelination readout; multiple orthogonal methods","pmids":["25536222"],"is_preprint":false},{"year":2007,"finding":"SOX9 and its coactivators SOX5/SOX6 (the SOX trio) transcriptionally induce S100A1 and S100B expression in chondrocytes, as shown by microarray, luciferase reporter assay, EMSA, and ChIP with identified enhancer elements. S100B overexpression suppresses hypertrophic chondrocyte differentiation and mineralization; silencing of both S100A1 and S100B stimulated terminal differentiation and reversed SOX-trio-mediated inhibition.","method":"Microarray, luciferase reporter assay, EMSA, chromatin immunoprecipitation, S100B overexpression and siRNA knockdown in chondrogenic cells","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — transcriptional mechanism established by ChIP and EMSA plus functional gain/loss-of-function with differentiation readout; multiple orthogonal methods","pmids":["17396138"],"is_preprint":false},{"year":1999,"finding":"In replicating myoblasts, S100B localizes to Golgi membranes, vimentin intermediate filaments (IFs), and microtubule (MT) structures as shown by immunofluorescence and immunogold electron microscopy. After colchicine treatment (MT disruption), a fraction of S100B remains with collapsed vimentin IFs while another fraction follows endoplasmic membranes, indicating S100B interacts with both MT and IF networks. In fused myotubes S100B is mostly associated with vimentin IFs, suggesting a role in regulating MT and IF dynamics.","method":"Immunofluorescence, immunogold electron microscopy, colchicine treatment (functional perturbation)","journal":"Cell calcium","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by immunogold EM with pharmacological perturbation; single lab, no biochemical binding confirmation in this paper","pmids":["10326676"],"is_preprint":false},{"year":2001,"finding":"S100B is expressed in microglia in a filamentous network and diffusely in the cytoplasm, and associates with intracellular membranes. During phagocytosis of opsonized Cryptococcus neoformans, S100B redistributes around phagosomes. IFN-γ treatment causes cell shape changes, S100B redistribution, and downregulation of S100B mRNA. Exogenous nanomolar-to-micromolar S100B increases IFN-γ-induced iNOS mRNA expression and NO secretion in microglia.","method":"Immunofluorescence, RT-PCR, Western blot, phagocytosis assay with live imaging, NO measurement","journal":"Glia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods in single lab; functional NO induction assay with localization data","pmids":["11180510"],"is_preprint":false},{"year":2013,"finding":"S100B promotes glioma growth in vivo by chemoattracting myeloid-derived macrophages/tumor-associated macrophages (TAM). S100B expression induced RAGE in vivo, but RAGE ablation did not significantly inhibit TAM infiltration, indicating RAGE-independent mechanisms. S100B upregulated CCL2 chemokine in high-S100B tumors, and CCL2 correlated with S100B expression in human glioma datasets.","method":"Stable transfection of GL261 glioma cells (S100B overexpression and knockdown), intracranial tumor implantation, RAGE knockout mice, chemokine analysis, TCGA database correlation","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic model with defined mechanism (CCL2 upregulation); single lab with bioinformatic support","pmids":["23719262"],"is_preprint":false},{"year":2013,"finding":"S100B upregulates TNF-α and M1 macrophage markers in macrophages via RAGE; TNF-α reciprocally augments S100B secretion from adipocytes. Silencing S100B or RAGE neutralization significantly ameliorated TNF-α hypersecretion from macrophages stimulated with adipocyte conditioned media, establishing a paracrine loop between adipocytes (S100B secretion) and macrophages (RAGE-mediated activation).","method":"siRNA knockdown of S100B, RAGE-neutralizing antibody, conditioned media transfer, co-culture, ELISA","journal":"Obesity (Silver Spring, Md.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic loop established by siRNA and antibody blockade; single lab, in vitro cell culture model","pmids":["23804363"],"is_preprint":false},{"year":2015,"finding":"S100B upregulates IL-1β and CCL22 in macrophages (RAW264.7 and primary bone marrow-derived). In the Experimental Autoimmune Uveoretinitis model, S100B deletion in mice resulted in significantly reduced disease severity, reduced macrophage infiltration, and reduction of CCL22 and IL-1β in retinas, establishing a role for S100B in promoting macrophage-dependent retinal inflammation.","method":"PCR array, real-time PCR, flow cytometry, ELISA, S100B knockout mouse model, EAU histological grading","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro mechanistic data confirmed in S100B KO in vivo model; single lab with multiple readouts","pmids":["26204512"],"is_preprint":false},{"year":2017,"finding":"S100B impairs oligodendrocyte differentiation (OPC to mature MBP+ OL transition and morphological maturation) and myelination at micromolar concentrations. These effects were abolished by the RAGE antagonist FPS-ZM1, establishing that elevated S100B acts through the S100B-RAGE axis to impair oligodendrogenesis. In organotypic cerebellar slices, elevated S100B also impaired myelination, compromised neuronal/synaptic integrity, induced astrogliosis, NF-κB activation, and inflammation.","method":"Primary OL cultures, organotypic cerebellar slice cultures, RAGE antagonist (FPS-ZM1) rescue, immunofluorescence, Western blot","journal":"Neuropharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological rescue with RAGE antagonist establishes mechanism; two culture models; single lab","pmids":["29126910"],"is_preprint":false},{"year":2018,"finding":"S100B promotes microglia M1 polarization with enhanced migration and inhibits M2 polarization. NF-κB is essential for S100B-mediated control of microglia M1/M2 polarization and migration. In vivo, S100B aggravated cerebral ischemia (MCAO model) and exacerbated microglia M1 polarization and migration.","method":"Real-time PCR, NF-κB pathway inhibition, migration assay, MCAO mouse model, S100B treatment in vivo","journal":"Inflammation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway inhibitor (NF-κB) mechanistic data confirmed in in vivo MCAO model; single lab","pmids":["30229393"],"is_preprint":false},{"year":2004,"finding":"Strain injury to neuronal-glial co-cultures causes immediate release of S100B; adding exogenous S100B (10–100 nM) at 15 seconds, 6 hours, or 24 hours post-injury reduced delayed neuronal death at 48 hours, demonstrating a direct neuroprotective role of S100B after traumatic injury.","method":"In vitro stretch injury model (Silastic membrane), exogenous S100B treatment at multiple time points, propidium iodide neuronal death assay","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro traumatic injury model with multiple time-point rescue; single lab, single method","pmids":["15584905"],"is_preprint":false},{"year":1999,"finding":"S100beta-induced apoptosis in human neuronal precursor NT2/D1 cells is regulated by Bcl-2: S100beta treatment down-regulated Bcl-2 protein; bcl-2 gene transfer elevated Bcl-2 and repressed S100beta-mediated cell death; antisense bcl-2 knockdown in differentiated (retinoic acid-treated, Bcl-2-high) NT2 cells increased susceptibility to S100beta-induced apoptosis.","method":"bcl-2 gene transfer, antisense oligonucleotide knockdown, retinoic acid differentiation, cell death assays","journal":"Brain research. Molecular brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function of Bcl-2 with functional apoptosis readout; single lab","pmids":["10381557"],"is_preprint":false},{"year":2020,"finding":"Pentamidine (an S100B inhibitor) disrupts S100B-wtp53 interaction in colon cancer biopsies, reducing S100B's ability to activate RAGE/phospho-p38 MAPK/NF-κB signaling, and restores wtp53 pro-apoptotic control (reduces iNOS, VEGF, IL-6 upregulation and rescues Bax). Niosomal pentamidine delivery (PENVE) was required for tissue penetration.","method":"Human biopsy cultures, immunoblot, EMSA, ELISA, biochemical assays for S100B-wtp53 interaction and downstream signaling","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic dissection in human tissue biopsies with multiple assays; single lab","pmids":["32022398"],"is_preprint":false},{"year":2015,"finding":"S100B knockdown in melanocytes increased apoptosis through inhibition of PI3K/AKT, NF-κB, and ERK activation, suggesting intracellular S100B protects melanocytes from chemically induced cytotoxicity. No RAGE expression was detected in melanocytes and CD166/ALCAM showed no significant function in melanocyte survival, pointing to intracellular (rather than RAGE-mediated) S100B function in this cell type.","method":"S100B siRNA knockdown, Western blot for PI3K/AKT, NF-κB, ERK signaling, flow cytometry, LDH assay","journal":"Experimental dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA with pathway analysis; single lab; negative RAGE finding mechanistically informative","pmids":["24451020"],"is_preprint":false},{"year":2015,"finding":"In mesangial cells, HG-induced Steap4 protein expression was dependent on S100B; protein-protein interaction between Steap4 and S100B was confirmed by mass spectrometry of immunoprecipitated S100B. S100B-induced Steap4 gene transcription is mediated through a STAT3 site in the Steap4 promoter (via JNK, PI3K, and JAK/STAT3 pathways). Steap4 overexpression attenuates S100B-induced collagen IV, fibronectin, COX-2, and TGF-β expression.","method":"Co-immunoprecipitation/mass spectrometry, Steap4 promoter mutation analysis, kinase inhibitors (SP600125, LY294002, AG490), Steap4 overexpression, streptozotocin diabetic mouse model","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS-confirmed protein interaction, promoter mutation, in vivo validation; single lab","pmids":["25817898"],"is_preprint":false}],"current_model":"S100B is a Ca2+-binding EF-hand homodimer (capable of forming higher-order tetramers/octamers) that functions both intracellularly—interacting with targets including p53, phosphoglucomutase, intermediate filaments, microtubules, and annexins in a Ca2+-dependent manner to regulate cell survival, proliferation, and cytoskeletal dynamics—and extracellularly by engaging RAGE (with tetrameric S100B binding RAGE at higher affinity than dimers) to activate downstream pathways including NF-κB, ERK1/2, Cdc42-Rac1-JNK, and Ras-Rac1, triggering iNOS/NO production, COX-2 upregulation, macrophage polarization, and context-dependent pro- or anti-apoptotic outcomes; S100B also suppresses Aβ42 aggregation in a Ca2+-dependent manner, inhibits p53 activity in melanoma to block apoptosis, promotes sympathetic innervation of thermogenic adipose tissue as a calsyntenin 3β-dependent secreted neurotropic factor, and its transcription is regulated by SOX10 (in Schwann cells), the SOX trio (in chondrocytes), alpha1-adrenergic/PKC signaling (in cardiomyocytes), and YAP/TAZ-PRDM16-C/EBPβ (in adipocytes)."},"narrative":{"mechanistic_narrative":"S100B is a Ca2+-binding EF-hand protein that operates as a dual-compartment signaling molecule, acting intracellularly to engage target proteins and extracellularly as a secreted ligand for the RAGE receptor [PMID:17660747, PMID:20587415]. Structurally it assembles beyond the homodimer into a tetrameric/octameric architecture, and the higher-order tetramer binds two RAGE molecules through the receptor V-domain with greater affinity than the dimer and drives stronger growth/survival signaling [PMID:17660747]. Intracellularly, Ca2+-dependent binding partners include p53—where S100B sequesters wild-type p53 to suppress its phosphorylation, target-gene induction (p21, PIDD), and Fas-mediated apoptosis in melanoma, an interaction that can be pharmacologically disrupted to restore p53 pro-apoptotic control [PMID:20587415, PMID:32022398]—as well as the metabolic enzyme phosphoglucomutase (which S100B stimulates), annexin VI, and the vimentin intermediate-filament and microtubule networks, consistent with roles in cytoskeletal dynamics [PMID:8894274, PMID:11108963, PMID:10326676]. Extracellular S100B signals through RAGE to activate NF-κB, ERK1/2, and parallel Cdc42-Rac1-JNK and Ras-Rac1 cascades, inducing COX-2, iNOS/NO production, and inflammatory mediators that drive microglial/macrophage M1 polarization and context-dependent neurotoxicity or neuroprotection [PMID:17660747, PMID:9375660, PMID:17023559, PMID:30229393, PMID:15584905]. S100B also acts as a Ca2+-dependent chaperone that suppresses Aβ42 primary and secondary nucleation by binding monomers, oligomers, and fibrils, protecting cells from amyloid toxicity [PMID:29963623]. As a secreted neurotrophic factor lacking a signal peptide, S100B is exported via calsyntenin 3β from thermogenic adipocytes to promote sympathetic innervation of adipose tissue [PMID:31043739]. Its transcription is cell-type-specifically controlled by SOX10 in Schwann cells (where S100B supports myelination), the SOX9/SOX5/SOX6 trio in chondrocytes (where it restrains hypertrophic differentiation), alpha1-adrenergic/PKC signaling in cardiomyocytes (where it serves as a negative-feedback brake on hypertrophy), and a YAP/TAZ-PRDM16-C/EBPβ axis in adipocytes [PMID:12388300, PMID:9677434, PMID:37925548, PMID:25536222, PMID:17396138].","teleology":[{"year":1994,"claim":"Established that S100B dosage in vivo drives glial and neuronal remodeling, framing it as an active modulator of brain tissue architecture rather than a passive marker.","evidence":"S100B transgenic mice with 2- and 7-fold elevation, with quantitative glial/neuronal markers and hippocampal histology","pmids":["8202493"],"confidence":"Medium","gaps":["Does not distinguish intracellular versus secreted S100B effects","Mechanism linking S100B to astrocytosis/axonal sprouting not defined"]},{"year":1996,"claim":"Identified the first intracellular Ca2+-dependent enzyme target, showing S100B is a regulator of metabolic enzyme activity and that S100 paralogs can have opposite functional effects.","evidence":"Reciprocal affinity chromatography, gel overlay, and phosphoglucomutase enzyme activity assay","pmids":["8894274"],"confidence":"Medium","gaps":["In vitro only; cellular relevance not tested","Binding interface on S100B not mapped"]},{"year":1997,"claim":"Demonstrated that extracellular S100B is neurotoxic through an astrocyte iNOS/NO intermediary, defining a non-cell-autonomous toxicity pathway.","evidence":"Astrocyte-neuron co-culture with NOS-inhibitor rescue and multiple cell-death readouts","pmids":["9375660"],"confidence":"High","gaps":["Receptor mediating S100B uptake/signaling not identified in this study","Concentration threshold for toxic versus trophic effect not resolved"]},{"year":1999,"claim":"Linked S100B to the cytoskeleton and apoptotic machinery, showing intracellular association with vimentin/microtubule networks and Bcl-2-dependent control of S100B-induced death.","evidence":"Immunogold EM with colchicine perturbation in myoblasts; bcl-2 gain/loss-of-function with apoptosis assays in neuronal precursors","pmids":["10326676","10381557"],"confidence":"Medium","gaps":["Direct biochemical binding to filaments not confirmed in localization study","How S100B engages the Bcl-2 axis mechanistically not defined"]},{"year":2002,"claim":"Resolved how S100B transcription is induced in the heart, establishing it as an alpha1A-adrenergic/PKC-driven negative-feedback brake on cardiomyocyte hypertrophy.","evidence":"Promoter deletion/luciferase analysis with adrenergic agonists/antagonists in cardiac myocytes; transgenic and forced-expression studies","pmids":["12388300","9677434"],"confidence":"Medium","gaps":["Whether the anti-hypertrophic effect is intracellular or RAGE-mediated unresolved at this stage","TEF-1/RTEF-1 regulatory logic not connected to downstream effectors"]},{"year":2006,"claim":"Dissected the extracellular S100B-RAGE signaling branch, showing it activates two parallel cascades (Cdc42-Rac1-JNK and Ras-Rac1-NF-κB) to induce COX-2 in microglia.","evidence":"Microglial culture with RAGE-dependent and pathway-specific inhibitor studies, Western blot and reporter assays","pmids":["17023559"],"confidence":"Medium","gaps":["Not independently replicated","Relative contribution of each cascade to inflammatory output not quantified"]},{"year":2007,"claim":"Provided the structural basis for ligand potency, showing S100B forms an octamer/tetramer that binds RAGE at higher affinity than the dimer and triggers stronger growth signaling.","evidence":"X-ray crystallography, analytical ultracentrifugation, and cell growth/survival assays","pmids":["17660747"],"confidence":"High","gaps":["In vivo relevance of higher-order oligomers not established","Downstream signaling differences between oligomeric states not mapped"]},{"year":2010,"claim":"Defined a key intracellular oncogenic mechanism: S100B binds and suppresses p53 to block apoptosis in melanoma, and a RAGE/ERK1/p53 extracellular branch drives apoptosis in cardiomyocytes.","evidence":"siRNA, gain-of-function, and pifithrin-alpha rescue in melanoma cells; S100B knockout mouse with post-MI phenotyping and signaling readouts","pmids":["20587415","20204434"],"confidence":"High","gaps":["Structural detail of the S100B-p53 interface not resolved here","Why the same protein is anti-apoptotic intracellularly yet pro-apoptotic via RAGE is unresolved"]},{"year":2014,"claim":"Established cell-type-specific transcriptional control by SOX factors, with SOX10 driving S100B in Schwann cells to support myelination and restrain proliferation.","evidence":"SOX10 overexpression/knockdown, promoter SOX-motif mapping, and DRG myelination co-culture; SOX trio ChIP/EMSA in chondrocytes","pmids":["25536222","17396138"],"confidence":"High","gaps":["Downstream effectors of S100B in myelination/chondrocyte differentiation not defined","Whether S100B acts intra- or extracellularly in these contexts not resolved"]},{"year":2018,"claim":"Revealed a Ca2+-dependent chaperone function: S100B suppresses Aβ42 primary and secondary nucleation by binding monomers, oligomers, and fibrils, protecting cells from amyloid toxicity.","evidence":"NMR mapping of the interaction site, thioflavin-T aggregation kinetics, and cell viability assays","pmids":["29963623"],"confidence":"High","gaps":["In vivo protective relevance in amyloid pathology not tested","Whether the chaperone role competes with RAGE-driven inflammation in situ unknown"]},{"year":2019,"claim":"Identified the mechanism of S100B secretion and its trophic action, showing calsyntenin 3β drives ER localization/secretion of signal-peptide-lacking S100B to promote sympathetic innervation of fat.","evidence":"Adipocyte loss/gain-of-function with genetic epistasis (KO phenocopy plus rescue) and in vitro neurite outgrowth assay","pmids":["31043739"],"confidence":"High","gaps":["Receptor mediating S100B's neurotrophic effect on sympathetic neurons not identified","Unconventional secretion route mechanistics beyond calsyntenin 3β dependence not detailed"]},{"year":2023,"claim":"Resolved upstream transcriptional gating in adipocytes, showing YAP/TAZ repress S100B by competing with C/EBPβ for PRDM16, with adrenergic signaling releasing repression to permit beige-fat innervation.","evidence":"Adipocyte Yap/Taz knockout, AAV-S100B rescue, co-IP of YAP/TAZ-PRDM16-C/EBPβ, and transcriptional reporters","pmids":["37925548"],"confidence":"High","gaps":["How adrenergic phosphorylation of YAP/TAZ is integrated with other S100B promoters not connected across tissues","Quantitative contribution to systemic thermogenesis not addressed"]},{"year":null,"claim":"How a single Ca2+-binding protein is partitioned between opposing intracellular (pro-survival, p53-suppressing, chaperone) and extracellular (RAGE-driven, often pro-inflammatory/cytotoxic) functions across cell types and concentrations remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking oligomeric state, concentration, and secretion to functional outcome","RAGE-independent extracellular mechanisms (e.g., CCL2 in glioma) incompletely mapped","In vivo balance of neurotoxic versus neuroprotective S100B not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,11]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3,5,24]},{"term_id":"GO:0044183","term_label":"protein folding chaperone","supporting_discovery_ids":[2]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[6,15]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[15,16]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[15]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[15]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[11]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,11,18]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,18,19,21]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,4,9]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[3,9,23]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[7,12,13,14]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[11,13,14]}],"complexes":[],"partners":["RAGE","TP53","PGM1","ANXA6","CLSTN3","PRDM16","STEAP4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P04271","full_name":"Protein S100-B","aliases":["S-100 protein beta chain","S-100 protein subunit beta","S100 calcium-binding protein B"],"length_aa":92,"mass_kda":10.7,"function":"Small zinc- and- and calcium-binding protein that is highly expressed in astrocytes and constitutes one of the most abundant soluble proteins in brain (PubMed:20950652, PubMed:6487634). Weakly binds calcium but binds zinc very tightly-distinct binding sites with different affinities exist for both ions on each monomer (PubMed:20950652, PubMed:6487634). Physiological concentrations of potassium ion antagonize the binding of both divalent cations, especially affecting high-affinity calcium-binding sites (By similarity). Acts as a neurotrophic factor that promotes astrocytosis and axonal proliferation (By similarity). Involved in innervation of thermogenic adipose tissue by acting as an adipocyte-derived neurotrophic factor that promotes sympathetic innervation of adipose tissue (By similarity). Binds to and initiates the activation of STK38 by releasing autoinhibitory intramolecular interactions within the kinase (By similarity). Interaction with AGER after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling (By similarity). Could assist ATAD3A cytoplasmic processing, preventing aggregation and favoring mitochondrial localization (PubMed:20351179). May mediate calcium-dependent regulation on many physiological processes by interacting with other proteins, such as TPR-containing proteins, and modulating their activity (PubMed:22399290)","subcellular_location":"Cytoplasm; Nucleus; Secreted","url":"https://www.uniprot.org/uniprotkb/P04271/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/S100B","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/S100B","total_profiled":1310},"omim":[{"mim_id":"621092","title":"IQ MOTIF-CONTAINING GTPase-ACTIVATING PROTEIN 3; IQGAP3","url":"https://www.omim.org/entry/621092"},{"mim_id":"615836","title":"SERINE/THREONINE PROTEIN KINASE 38-LIKE PROTEIN; STK38L","url":"https://www.omim.org/entry/615836"},{"mim_id":"612349","title":"PHENYLALANINE HYDROXYLASE; PAH","url":"https://www.omim.org/entry/612349"},{"mim_id":"611324","title":"CALSYNTENIN 3; CLSTN3","url":"https://www.omim.org/entry/611324"},{"mim_id":"606964","title":"SERINE/THREONINE PROTEIN KINASE 38; STK38","url":"https://www.omim.org/entry/606964"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Primary cilium","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Microtubules","reliability":"Additional"},{"location":"Cytokinetic bridge","reliability":"Additional"},{"location":"Mitotic spindle","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":4757.1}],"url":"https://www.proteinatlas.org/search/S100B"},"hgnc":{"alias_symbol":["S100beta"],"prev_symbol":[]},"alphafold":{"accession":"P04271","domains":[{"cath_id":"1.10.238.10","chopping":"2-90","consensus_level":"high","plddt":92.3271,"start":2,"end":90}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P04271","model_url":"https://alphafold.ebi.ac.uk/files/AF-P04271-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P04271-F1-predicted_aligned_error_v6.png","plddt_mean":91.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=S100B","jax_strain_url":"https://www.jax.org/strain/search?query=S100B"},"sequence":{"accession":"P04271","fasta_url":"https://rest.uniprot.org/uniprotkb/P04271.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P04271/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P04271"}},"corpus_meta":[{"pmid":"19110011","id":"PMC_19110011","title":"S100B's double life: intracellular regulator and extracellular signal.","date":"2008","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19110011","citation_count":585,"is_preprint":false},{"pmid":"12645009","id":"PMC_12645009","title":"S100B in brain damage and neurodegeneration.","date":"2003","source":"Microscopy research and technique","url":"https://pubmed.ncbi.nlm.nih.gov/12645009","citation_count":480,"is_preprint":false},{"pmid":"30144068","id":"PMC_30144068","title":"The S100B story: from biomarker to active factor in neural injury.","date":"2018","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30144068","citation_count":314,"is_preprint":false},{"pmid":"9375660","id":"PMC_9375660","title":"S100beta induces neuronal cell death through nitric oxide release from astrocytes.","date":"1997","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9375660","citation_count":296,"is_preprint":false},{"pmid":"11139112","id":"PMC_11139112","title":"Elimination of S100B and renal function after cardiac surgery.","date":"2000","source":"Journal of cardiothoracic and vascular anesthesia","url":"https://pubmed.ncbi.nlm.nih.gov/11139112","citation_count":210,"is_preprint":false},{"pmid":"17660747","id":"PMC_17660747","title":"Structural and functional insights into RAGE activation by multimeric S100B.","date":"2007","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/17660747","citation_count":209,"is_preprint":false},{"pmid":"17348038","id":"PMC_17348038","title":"S100B in neuropathologic states: the CRP of the brain?","date":"2007","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/17348038","citation_count":202,"is_preprint":false},{"pmid":"22145907","id":"PMC_22145907","title":"The S100B protein in biological fluids: more than a lifelong biomarker of brain distress.","date":"2012","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22145907","citation_count":194,"is_preprint":false},{"pmid":"11180510","id":"PMC_11180510","title":"S100B expression in and effects on microglia.","date":"2001","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/11180510","citation_count":158,"is_preprint":false},{"pmid":"17522796","id":"PMC_17522796","title":"Reliability of S100B in predicting severity of central nervous system injury.","date":"2007","source":"Neurocritical care","url":"https://pubmed.ncbi.nlm.nih.gov/17522796","citation_count":156,"is_preprint":false},{"pmid":"8202493","id":"PMC_8202493","title":"Astrocytosis and axonal proliferation in the hippocampus of S100b transgenic mice.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8202493","citation_count":154,"is_preprint":false},{"pmid":"31043739","id":"PMC_31043739","title":"Innervation of thermogenic adipose tissue via a calsyntenin 3β-S100b axis.","date":"2019","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/31043739","citation_count":154,"is_preprint":false},{"pmid":"15782413","id":"PMC_15782413","title":"Spatial and temporal expression of S100B in cells of oligodendrocyte lineage.","date":"2005","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/15782413","citation_count":137,"is_preprint":false},{"pmid":"17023559","id":"PMC_17023559","title":"S100B binding to RAGE in microglia stimulates COX-2 expression.","date":"2006","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/17023559","citation_count":122,"is_preprint":false},{"pmid":"21303299","id":"PMC_21303299","title":"S100B protein in neurodegenerative disorders.","date":"2011","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21303299","citation_count":114,"is_preprint":false},{"pmid":"12446464","id":"PMC_12446464","title":"S100B protein in biological fluids: a tool for perinatal medicine.","date":"2002","source":"Clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12446464","citation_count":103,"is_preprint":false},{"pmid":"20587415","id":"PMC_20587415","title":"The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20587415","citation_count":96,"is_preprint":false},{"pmid":"37298554","id":"PMC_37298554","title":"The S100B Protein: A Multifaceted Pathogenic Factor More Than a Biomarker.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37298554","citation_count":94,"is_preprint":false},{"pmid":"23701298","id":"PMC_23701298","title":"Serum S100B represents a new biomarker for mood disorders.","date":"2013","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/23701298","citation_count":94,"is_preprint":false},{"pmid":"17396138","id":"PMC_17396138","title":"S100A1 and S100B, transcriptional targets of SOX trio, inhibit terminal differentiation of chondrocytes.","date":"2007","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/17396138","citation_count":94,"is_preprint":false},{"pmid":"30499235","id":"PMC_30499235","title":"Cellular and molecular mechanisms of sarcopenia: the S100B perspective.","date":"2018","source":"Journal of cachexia, sarcopenia and muscle","url":"https://pubmed.ncbi.nlm.nih.gov/30499235","citation_count":90,"is_preprint":false},{"pmid":"23719262","id":"PMC_23719262","title":"S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages.","date":"2013","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/23719262","citation_count":86,"is_preprint":false},{"pmid":"23580916","id":"PMC_23580916","title":"S100B protein in tissue development, repair and regeneration.","date":"2013","source":"World journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23580916","citation_count":80,"is_preprint":false},{"pmid":"21465945","id":"PMC_21465945","title":"Usefulness of S100B protein in neurological disorders.","date":"2011","source":"JPMA. The Journal of the Pakistan Medical Association","url":"https://pubmed.ncbi.nlm.nih.gov/21465945","citation_count":79,"is_preprint":false},{"pmid":"11809917","id":"PMC_11809917","title":"Circulating S100beta protein is increased in intrauterine growth-retarded fetuses.","date":"2002","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/11809917","citation_count":78,"is_preprint":false},{"pmid":"21779383","id":"PMC_21779383","title":"S100B and APP promote a gliocentric shift and impaired neurogenesis in Down syndrome neural progenitors.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21779383","citation_count":77,"is_preprint":false},{"pmid":"19679874","id":"PMC_19679874","title":"Characterization of RAGE, HMGB1, and S100beta in inflammation-induced preterm birth and fetal tissue injury.","date":"2009","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19679874","citation_count":74,"is_preprint":false},{"pmid":"15328028","id":"PMC_15328028","title":"Relationship between S100beta and GFAP expression in astrocytes during infarction and glial scar formation after mild transient ischemia.","date":"2004","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/15328028","citation_count":73,"is_preprint":false},{"pmid":"37047574","id":"PMC_37047574","title":"S100B, Actor and Biomarker of Mild Traumatic Brain Injury.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37047574","citation_count":71,"is_preprint":false},{"pmid":"9647074","id":"PMC_9647074","title":"Cerebral emboli and serum S100beta during cardiac operations.","date":"1998","source":"The Annals of thoracic surgery","url":"https://pubmed.ncbi.nlm.nih.gov/9647074","citation_count":70,"is_preprint":false},{"pmid":"15006498","id":"PMC_15006498","title":"S100B in schizophrenic psychosis.","date":"2004","source":"International review of neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/15006498","citation_count":69,"is_preprint":false},{"pmid":"9383091","id":"PMC_9383091","title":"GFAP and S100beta expression in the cortex and hippocampus in response to mild cortical contusion.","date":"1997","source":"Journal of neurotrauma","url":"https://pubmed.ncbi.nlm.nih.gov/9383091","citation_count":60,"is_preprint":false},{"pmid":"15670788","id":"PMC_15670788","title":"SNPs and haplotypes in the S100B gene reveal association with schizophrenia.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15670788","citation_count":59,"is_preprint":false},{"pmid":"18472341","id":"PMC_18472341","title":"S100B is expressed in, and released from, OLN-93 oligodendrocytes: Influence of serum and glucose deprivation.","date":"2008","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18472341","citation_count":58,"is_preprint":false},{"pmid":"29963623","id":"PMC_29963623","title":"The neuronal S100B protein is a calcium-tuned suppressor of amyloid-β aggregation.","date":"2018","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/29963623","citation_count":57,"is_preprint":false},{"pmid":"9389498","id":"PMC_9389498","title":"S100A1 and S100B expression and target proteins in type I diabetes.","date":"1997","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9389498","citation_count":54,"is_preprint":false},{"pmid":"20827422","id":"PMC_20827422","title":"The Calcium-Dependent Interaction of S100B with Its Protein Targets.","date":"2010","source":"Cardiovascular psychiatry and neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20827422","citation_count":51,"is_preprint":false},{"pmid":"23804363","id":"PMC_23804363","title":"The role of S100B in the interaction between adipocytes and macrophages.","date":"2013","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/23804363","citation_count":50,"is_preprint":false},{"pmid":"15023104","id":"PMC_15023104","title":"Cerebral and extracerebral release of protein S100B in cardiac surgical patients.","date":"2004","source":"Anaesthesia","url":"https://pubmed.ncbi.nlm.nih.gov/15023104","citation_count":49,"is_preprint":false},{"pmid":"15584905","id":"PMC_15584905","title":"S100B protein is released by in vitro trauma and reduces delayed neuronal injury.","date":"2004","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15584905","citation_count":48,"is_preprint":false},{"pmid":"8894274","id":"PMC_8894274","title":"Identification of an S100A1/S100B target protein: phosphoglucomutase.","date":"1996","source":"Cell calcium","url":"https://pubmed.ncbi.nlm.nih.gov/8894274","citation_count":48,"is_preprint":false},{"pmid":"23438158","id":"PMC_23438158","title":"S100B and schizophrenia.","date":"2013","source":"Psychiatry and clinical neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/23438158","citation_count":46,"is_preprint":false},{"pmid":"29345293","id":"PMC_29345293","title":"S100B expression in breast cancer as a predictive marker for cancer metastasis.","date":"2017","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29345293","citation_count":46,"is_preprint":false},{"pmid":"17350141","id":"PMC_17350141","title":"S100B content and secretion decrease in astrocytes cultured in high-glucose medium.","date":"2007","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/17350141","citation_count":46,"is_preprint":false},{"pmid":"25990800","id":"PMC_25990800","title":"S100B and ADMA in cerebral small vessel disease and cognitive dysfunction.","date":"2015","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25990800","citation_count":45,"is_preprint":false},{"pmid":"23256816","id":"PMC_23256816","title":"The evolution of S100B inhibitors for the treatment of malignant melanoma.","date":"2013","source":"Future medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23256816","citation_count":45,"is_preprint":false},{"pmid":"25536222","id":"PMC_25536222","title":"SOX10 transactivates S100B to suppress Schwann cell proliferation and to promote myelination.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25536222","citation_count":45,"is_preprint":false},{"pmid":"30229393","id":"PMC_30229393","title":"S100B promotes microglia M1 polarization and migration to aggravate cerebral ischemia.","date":"2018","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/30229393","citation_count":45,"is_preprint":false},{"pmid":"29959432","id":"PMC_29959432","title":"S100B immunization triggers NFκB and complement activation in an autoimmune glaucoma model.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29959432","citation_count":42,"is_preprint":false},{"pmid":"21376255","id":"PMC_21376255","title":"S100B transgenic mice develop features of Parkinson's disease.","date":"2011","source":"Archives of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/21376255","citation_count":42,"is_preprint":false},{"pmid":"29126910","id":"PMC_29126910","title":"Impaired oligodendrogenesis and myelination by elevated S100B levels during neurodevelopment.","date":"2017","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29126910","citation_count":39,"is_preprint":false},{"pmid":"15921704","id":"PMC_15921704","title":"The ischemic rat heart releases S100B.","date":"2005","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15921704","citation_count":38,"is_preprint":false},{"pmid":"35190890","id":"PMC_35190890","title":"Neuron Specific Enolase, S100-beta protein and progranulin as diagnostic biomarkers of status epilepticus.","date":"2022","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35190890","citation_count":37,"is_preprint":false},{"pmid":"27279465","id":"PMC_27279465","title":"Higher Plasma S100B Concentrations in Schizophrenia Patients, and Dependently Associated with Inflammatory Markers.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27279465","citation_count":36,"is_preprint":false},{"pmid":"12927678","id":"PMC_12927678","title":"S100B testing in pregnancy.","date":"2003","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12927678","citation_count":34,"is_preprint":false},{"pmid":"33957300","id":"PMC_33957300","title":"Alarmins (IL-33, sST2, HMGB1, and S100B) as potential biomarkers for schizophrenia.","date":"2021","source":"Journal of psychiatric research","url":"https://pubmed.ncbi.nlm.nih.gov/33957300","citation_count":34,"is_preprint":false},{"pmid":"12527118","id":"PMC_12527118","title":"Human milk contains S100B protein.","date":"2003","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12527118","citation_count":31,"is_preprint":false},{"pmid":"26204512","id":"PMC_26204512","title":"S100B Up-Regulates Macrophage Production of IL1β and CCL22 and Influences Severity of Retinal Inflammation.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26204512","citation_count":31,"is_preprint":false},{"pmid":"19330775","id":"PMC_19330775","title":"Risk variants in the S100B gene predict elevated S100B serum concentrations in healthy individuals.","date":"2010","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19330775","citation_count":30,"is_preprint":false},{"pmid":"10326676","id":"PMC_10326676","title":"Replicating myoblasts and fused myotubes express the calcium-regulated proteins S100A1 and S100B.","date":"1999","source":"Cell calcium","url":"https://pubmed.ncbi.nlm.nih.gov/10326676","citation_count":30,"is_preprint":false},{"pmid":"32022398","id":"PMC_32022398","title":"Pentamidine niosomes thwart S100B effects in human colon carcinoma biopsies favouring wtp53 rescue.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32022398","citation_count":30,"is_preprint":false},{"pmid":"25669696","id":"PMC_25669696","title":"S100B blood levels and childhood trauma in adolescent inpatients.","date":"2014","source":"Journal of psychiatric research","url":"https://pubmed.ncbi.nlm.nih.gov/25669696","citation_count":29,"is_preprint":false},{"pmid":"11108963","id":"PMC_11108963","title":"S100A1 and S100B interactions with annexins.","date":"2000","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11108963","citation_count":29,"is_preprint":false},{"pmid":"22286962","id":"PMC_22286962","title":"S100B protein as a possible participant in the brain metastasis of NSCLC.","date":"2012","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/22286962","citation_count":28,"is_preprint":false},{"pmid":"16699054","id":"PMC_16699054","title":"Raised serum S100B protein levels in neuropsychiatric lupus.","date":"2006","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/16699054","citation_count":28,"is_preprint":false},{"pmid":"34854356","id":"PMC_34854356","title":"Correlation between S100B and severity of depression in MDD: A meta-analysis.","date":"2021","source":"The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/34854356","citation_count":27,"is_preprint":false},{"pmid":"23296623","id":"PMC_23296623","title":"Clinical use of the calcium-binding S100B protein.","date":"2013","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/23296623","citation_count":27,"is_preprint":false},{"pmid":"12388300","id":"PMC_12388300","title":"Regulation of the S100B gene by alpha 1-adrenergic stimulation in cardiac myocytes.","date":"2002","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12388300","citation_count":27,"is_preprint":false},{"pmid":"27652205","id":"PMC_27652205","title":"S100B and S100B autoantibody as biomarkers for early detection of brain metastases in lung cancer.","date":"2016","source":"Translational lung cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27652205","citation_count":26,"is_preprint":false},{"pmid":"27013967","id":"PMC_27013967","title":"Serum S100B Protein is Specifically Related to White Matter Changes in Schizophrenia.","date":"2016","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27013967","citation_count":26,"is_preprint":false},{"pmid":"24402969","id":"PMC_24402969","title":"S100A1 and S100B expression patterns identify differentiation status of human articular chondrocytes.","date":"2014","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24402969","citation_count":24,"is_preprint":false},{"pmid":"32871787","id":"PMC_32871787","title":"Tau, S100B and NSE as Blood Biomarkers in Acute Cerebrovascular Events.","date":"2020","source":"In vivo (Athens, Greece)","url":"https://pubmed.ncbi.nlm.nih.gov/32871787","citation_count":24,"is_preprint":false},{"pmid":"27925190","id":"PMC_27925190","title":"S100A1 and S100B: Calcium Sensors at the Cross-Roads of Multiple Chondrogenic Pathways.","date":"2017","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27925190","citation_count":23,"is_preprint":false},{"pmid":"12834486","id":"PMC_12834486","title":"Expression of S100A2 and S100B proteins in epithelial tumors of the skin.","date":"2003","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12834486","citation_count":23,"is_preprint":false},{"pmid":"10381557","id":"PMC_10381557","title":"Bcl-2 expression regulates cell sensitivity to S100beta-mediated apoptosis.","date":"1999","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/10381557","citation_count":23,"is_preprint":false},{"pmid":"29764272","id":"PMC_29764272","title":"Does S100B have a potential role in affective disorders? A literature review.","date":"2018","source":"Nordic journal of psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/29764272","citation_count":22,"is_preprint":false},{"pmid":"24211224","id":"PMC_24211224","title":"S100B as a glial cell marker in diabetic peripheral neuropathy.","date":"2013","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/24211224","citation_count":22,"is_preprint":false},{"pmid":"20204434","id":"PMC_20204434","title":"S100B: a multifunctional role in cardiovascular pathophysiology.","date":"2010","source":"Amino acids","url":"https://pubmed.ncbi.nlm.nih.gov/20204434","citation_count":22,"is_preprint":false},{"pmid":"25215112","id":"PMC_25215112","title":"S100B protein in serum is elevated after global cerebral ischemic injury.","date":"2013","source":"World journal of emergency medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25215112","citation_count":22,"is_preprint":false},{"pmid":"32772615","id":"PMC_32772615","title":"S100B protein: general characteristics and pathophysiological implications in the Central Nervous System.","date":"2020","source":"The International journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32772615","citation_count":21,"is_preprint":false},{"pmid":"28696163","id":"PMC_28696163","title":"Evaluation of dietary and lifestyle changes as modifiers of S100β levels in Alzheimer's disease.","date":"2017","source":"Nutritional neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/28696163","citation_count":21,"is_preprint":false},{"pmid":"17187827","id":"PMC_17187827","title":"Plasma S100beta and NSE levels and progression in multiple sclerosis.","date":"2006","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17187827","citation_count":21,"is_preprint":false},{"pmid":"25852479","id":"PMC_25852479","title":"Differential temporal expression of S100β in developing rat brain.","date":"2015","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25852479","citation_count":21,"is_preprint":false},{"pmid":"14530577","id":"PMC_14530577","title":"S100B and cardiac surgery: possibilities and limitations.","date":"2003","source":"Restorative neurology and neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/14530577","citation_count":21,"is_preprint":false},{"pmid":"9677434","id":"PMC_9677434","title":"Induction of S100b in myocardium: an intrinsic inhibitor of cardiac hypertrophy.","date":"1998","source":"Canadian journal of applied physiology = Revue canadienne de physiologie appliquee","url":"https://pubmed.ncbi.nlm.nih.gov/9677434","citation_count":20,"is_preprint":false},{"pmid":"28435992","id":"PMC_28435992","title":"Elevated Plasma S100B, Psychotic Symptoms, and Cognition in Schizophrenia.","date":"2018","source":"The Psychiatric quarterly","url":"https://pubmed.ncbi.nlm.nih.gov/28435992","citation_count":20,"is_preprint":false},{"pmid":"22130006","id":"PMC_22130006","title":"S100B proteins in febrile seizures.","date":"2011","source":"Seizure","url":"https://pubmed.ncbi.nlm.nih.gov/22130006","citation_count":20,"is_preprint":false},{"pmid":"34948360","id":"PMC_34948360","title":"S100B Protein as a Therapeutic Target in Multiple Sclerosis: The S100B Inhibitor Arundic Acid Protects from Chronic Experimental Autoimmune Encephalomyelitis.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34948360","citation_count":20,"is_preprint":false},{"pmid":"25877001","id":"PMC_25877001","title":"Polymorphisms in DCDC2 and S100B associate with developmental dyslexia.","date":"2015","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25877001","citation_count":20,"is_preprint":false},{"pmid":"25342137","id":"PMC_25342137","title":"Normal cerebellar development in S100B-deficient mice.","date":"2015","source":"Cerebellum (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25342137","citation_count":19,"is_preprint":false},{"pmid":"24451020","id":"PMC_24451020","title":"S100B as a potential biomarker for the detection of cytotoxicity of melanocytes.","date":"2014","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/24451020","citation_count":19,"is_preprint":false},{"pmid":"14716532","id":"PMC_14716532","title":"Carotid endarterectomy and gliofibrillar S100b protein release.","date":"2003","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/14716532","citation_count":19,"is_preprint":false},{"pmid":"28399921","id":"PMC_28399921","title":"S100β as a serum marker in endocrine resistant breast cancer.","date":"2017","source":"BMC medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28399921","citation_count":19,"is_preprint":false},{"pmid":"15030908","id":"PMC_15030908","title":"Over-expression of S100B protein in children with cerebral palsy or delayed development.","date":"2004","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/15030908","citation_count":18,"is_preprint":false},{"pmid":"21864523","id":"PMC_21864523","title":"Reference values for venous and capillary S100B in children.","date":"2011","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21864523","citation_count":18,"is_preprint":false},{"pmid":"37925548","id":"PMC_37925548","title":"Transcriptional repression of beige fat innervation via a YAP/TAZ-S100B axis.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37925548","citation_count":17,"is_preprint":false},{"pmid":"25704302","id":"PMC_25704302","title":"The clinical and diagnostic utility of S100B in preterm newborns.","date":"2015","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25704302","citation_count":17,"is_preprint":false},{"pmid":"34550453","id":"PMC_34550453","title":"New insights into the role and origin of pituitary S100β-positive cells.","date":"2021","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/34550453","citation_count":17,"is_preprint":false},{"pmid":"31957846","id":"PMC_31957846","title":"S100B as a new fecal biomarker of inflammatory bowel diseases.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31957846","citation_count":17,"is_preprint":false},{"pmid":"25817898","id":"PMC_25817898","title":"Steap4 attenuates high glucose and S100B-induced effects in mesangial cells.","date":"2015","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25817898","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46884,"output_tokens":7402,"usd":0.125841,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16771,"output_tokens":4664,"usd":0.100227,"stage2_stop_reason":"end_turn"},"total_usd":0.226068,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"X-ray crystal structure of human Ca2+-loaded S100B at 1.9 Å resolution revealed an octameric architecture of four homodimeric units arranged as two tetramers. Tetrameric S100B binds RAGE with higher affinity than dimeric S100B, and analytical ultracentrifugation showed the tetramer binds two RAGE molecules via the V-domain. Tetrameric S100B caused stronger activation of cell growth and survival than dimeric S100B.\",\n      \"method\": \"X-ray crystallography, size-exclusion chromatography, analytical ultracentrifugation, cell growth/survival assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with biophysical binding studies and functional cell assays in a single rigorous study\",\n      \"pmids\": [\"17660747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"High concentrations of S100beta treatment of astrocytes activates inducible nitric oxide synthase (iNOS) and causes NO release; in astrocyte-neuron co-cultures, this S100beta-induced NO from astrocytes caused neuronal cell death (both necrosis and apoptosis). Neuronal death was blocked by a specific NOS inhibitor, establishing that S100B acts through iNOS/NO in astrocytes to cause neurotoxicity.\",\n      \"method\": \"Astrocyte-neuron co-culture, NOS inhibitor pharmacology, cell death assays (propidium iodide, TUNEL, apoptosis morphology)\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean pharmacological rescue (NOS inhibitor blocks death), replicated with multiple readouts of cell death, consistent with independent studies\",\n      \"pmids\": [\"9375660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"S100B suppresses Aβ42 aggregation in a calcium-dependent manner. NMR experiments showed that the interaction occurs at a promiscuous peptide-binding region within the interfacial cleft of the S100B homodimer; calcium binding to S100B favors interaction with monomeric Aβ42, possibly inducing an α-helical conformer that locks aggregation. S100B delays onset of Aβ42 aggregation by inhibiting primary nucleation and inhibits fibril surface-catalyzed secondary nucleation by binding oligomers and fibrils. S100B protected cells from Aβ42-mediated toxicity.\",\n      \"method\": \"NMR spectroscopy, thioflavin-T aggregation kinetics assays, cell viability/apoptosis assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structural (NMR) plus in vitro reconstitution of aggregation kinetics plus cell-based functional validation in one study\",\n      \"pmids\": [\"29963623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"S100B forms a complex with p53 in malignant melanoma cells (C8146A). siRNA knockdown of S100B increased p53 protein, phosphorylated p53, and p53 target gene products (p21, PIDD) without changing p53 mRNA, and restored p53-dependent apoptosis via the Fas death receptor pathway (caspase 3/8 activation, PARP cleavage). Rescue with pifithrin-alpha (p53 inhibitor) reversed siRNA(S100B)-induced apoptosis, confirming the mechanism. Introduction of S100B into S100B-null cells reduced UV-induced apoptosis 7-fold.\",\n      \"method\": \"siRNA knockdown, Western blot, caspase activation assays, DNA laddering, flow cytometry, p53 inhibitor rescue\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (siRNA, gain-of-function, pharmacological rescue) in a single rigorous study with clean mechanistic dissection\",\n      \"pmids\": [\"20587415\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Extracellular S100B up-regulates cyclooxygenase-2 (COX-2) expression in microglia via RAGE in a concentration-dependent manner. Two independent downstream pathways were identified: a Cdc42-Rac1-JNK pathway and a Ras-Rac1-NF-κB pathway, both activated independently by S100B-RAGE signaling.\",\n      \"method\": \"Microglial cell culture, RAGE-dependent pharmacological inhibition, pathway inhibitor studies, Western blot, reporter assays\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway dissection with multiple inhibitors in a single lab; mechanistically detailed but not independently replicated\",\n      \"pmids\": [\"17023559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Phosphoglucomutase was identified as an intracellular S100B (and S100A1) target protein. S100B bound phosphoglucomutase-Sepharose in a calcium-dependent manner (confirmed by reciprocal affinity chromatography and gel overlay). S100B stimulated phosphoglucomutase activity in a calcium-dependent manner, in contrast to S100A1 which inhibited it. Other calcium-binding proteins (calmodulin, troponin C, parvalbumin, α-lactalbumin) had no effect.\",\n      \"method\": \"Gel overlay, affinity chromatography (reciprocal), enzyme activity assay\",\n      \"journal\": \"Cell calcium\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro biochemical reconstitution with reciprocal affinity chromatography and functional enzyme assay; single lab\",\n      \"pmids\": [\"8894274\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"S100A1 and S100B bind annexin VI in a Ca2+-dependent manner, forming heterotetramers in which an S100 homodimer crossbridges two copies of annexin VI. The C-terminal half of annexin VI (annexin VI-b), but not the N-terminal half (annexin VI-a), blocks the inhibitory effect of S100A1 and S100B on intermediate filament assembly. The C-terminal extension of S100B is not part of the surface implicated in annexin VI recognition. S100 proteins permeabilize membrane bilayers similarly to annexins.\",\n      \"method\": \"Co-immunoprecipitation/binding assays, intermediate filament assembly assay, liposome permeabilization and calcium influx assay\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays with domain mapping; single lab, in vitro\",\n      \"pmids\": [\"11108963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Alpha1-adrenergic stimulation induces the S100B gene in cardiac myocytes specifically through the alpha1A-adrenergic receptor and the PKC signaling pathway. A basic promoter (spanning 162 bp upstream of the transcription initiation site) was identified as essential for transcription, along with positive and negative regulatory elements. TEF-1 transrepressed and RTEF-1 transactivated the maximal S100B promoter. This identifies S100B as a negative feedback regulator of alpha1-adrenergic/PKC-driven cardiac hypertrophy.\",\n      \"method\": \"Luciferase reporter assays with sequential 5'-deletion constructs, transfection of cardiac myocytes, adrenergic receptor agonists/antagonists\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic promoter deletion analysis with multiple regulatory element identifications; single lab\",\n      \"pmids\": [\"12388300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Forced expression of S100B in neonatal rat cardiac myocyte cultures and high-level expression in transgenic mouse hearts inhibits cardiac hypertrophy and associated phenotype by modulating protein kinase C-dependent pathways. S100B is induced after myocardial infarction and acts as a negative feedback regulator limiting cardiomyocyte hypertrophy.\",\n      \"method\": \"Forced gene expression in primary myocyte cultures, transgenic mouse model, PKC pathway analysis\",\n      \"journal\": \"Canadian journal of applied physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro overexpression plus transgenic mouse validation; single lab, limited mechanistic detail in abstract\",\n      \"pmids\": [\"9677434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"S100B induces apoptosis in cardiomyocytes via an extracellular mechanism by engaging RAGE and activating ERK1/2 and p53 signaling. Knocking out S100B augmented hypertrophy, decreased apoptosis, and preserved cardiac function following myocardial infarction.\",\n      \"method\": \"S100B knockout mouse model, exogenous S100B treatment, Western blot for ERK1/2 and p53 signaling\",\n      \"journal\": \"Amino acids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO model with defined phenotypic and signaling readout; single lab review citing prior experimental work\",\n      \"pmids\": [\"20204434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Transgenic mice expressing 2-fold and 7-fold elevated S100B show concomitant astrocytosis and axonal sprouting in the hippocampus (elevated GFAP, neurofilament L, phosphorylated NF-H/M, beta-tubulin), demonstrating that elevated S100B in vivo promotes both astrocyte morphological changes and neurite proliferation, particularly in the dentate gyrus.\",\n      \"method\": \"S100B transgenic mouse model, Western blot, immunocytochemistry\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo transgenic gain-of-function with quantitative protein markers and histology; single lab\",\n      \"pmids\": [\"8202493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Calsyntenin 3β (a novel ER protein in thermogenic adipocytes) promotes ER localization and secretion of S100B from brown adipocytes despite S100B lacking a signal peptide. S100B stimulates neurite outgrowth from sympathetic neurons in vitro. S100B deficiency phenocopies calsyntenin 3β deficiency (reduced sympathetic innervation of adipose tissue), and forced S100B expression in brown adipocytes rescues the innervation defect caused by calsyntenin 3β ablation.\",\n      \"method\": \"Genetic loss/gain-of-function in adipocytes, in vitro neurite outgrowth assay, rescue experiments with forced S100B expression\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (KO phenocopy + rescue), in vitro functional assay, multiple orthogonal approaches in high-impact study\",\n      \"pmids\": [\"31043739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"YAP/TAZ in adipocytes transcriptionally repress S100B expression by competing with C/EBPβ for binding to the zinc finger-2 domain of PRDM16, thereby suppressing PRDM16-C/EBPβ-mediated S100b transcription. Adrenergic stimulation phosphorylates and inactivates YAP/TAZ, releasing this repression to allow S100B expression and sympathetic innervation of beige fat.\",\n      \"method\": \"Adipocyte-specific Yap/Taz knockout, AAV-S100B overexpression, co-immunoprecipitation of YAP/TAZ-PRDM16-C/EBPβ interactions, transcriptional reporter assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO plus rescue, molecular mechanism defined by protein-protein interaction studies and transcriptional assays, multiple orthogonal methods\",\n      \"pmids\": [\"37925548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SOX10 transcription factor transactivates the S100B promoter in Schwann cells through three core response elements in the S100B promoter and intron 1 containing SOX motifs. SOX10 overexpression dramatically induces S100B expression; SOX10 knockdown suppresses S100B. Knockdown of either SOX10 or S100B enhances Schwann cell proliferation, and S100B knockdown impairs myelination in dorsal root ganglion co-cultures.\",\n      \"method\": \"SOX10 overexpression/shRNA knockdown, S100B shRNA knockdown, luciferase reporter with SOX motif mapping, DRG myelination assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — transcriptional mechanism defined by promoter mapping plus gain- and loss-of-function with functional myelination readout; multiple orthogonal methods\",\n      \"pmids\": [\"25536222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SOX9 and its coactivators SOX5/SOX6 (the SOX trio) transcriptionally induce S100A1 and S100B expression in chondrocytes, as shown by microarray, luciferase reporter assay, EMSA, and ChIP with identified enhancer elements. S100B overexpression suppresses hypertrophic chondrocyte differentiation and mineralization; silencing of both S100A1 and S100B stimulated terminal differentiation and reversed SOX-trio-mediated inhibition.\",\n      \"method\": \"Microarray, luciferase reporter assay, EMSA, chromatin immunoprecipitation, S100B overexpression and siRNA knockdown in chondrogenic cells\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — transcriptional mechanism established by ChIP and EMSA plus functional gain/loss-of-function with differentiation readout; multiple orthogonal methods\",\n      \"pmids\": [\"17396138\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"In replicating myoblasts, S100B localizes to Golgi membranes, vimentin intermediate filaments (IFs), and microtubule (MT) structures as shown by immunofluorescence and immunogold electron microscopy. After colchicine treatment (MT disruption), a fraction of S100B remains with collapsed vimentin IFs while another fraction follows endoplasmic membranes, indicating S100B interacts with both MT and IF networks. In fused myotubes S100B is mostly associated with vimentin IFs, suggesting a role in regulating MT and IF dynamics.\",\n      \"method\": \"Immunofluorescence, immunogold electron microscopy, colchicine treatment (functional perturbation)\",\n      \"journal\": \"Cell calcium\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by immunogold EM with pharmacological perturbation; single lab, no biochemical binding confirmation in this paper\",\n      \"pmids\": [\"10326676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"S100B is expressed in microglia in a filamentous network and diffusely in the cytoplasm, and associates with intracellular membranes. During phagocytosis of opsonized Cryptococcus neoformans, S100B redistributes around phagosomes. IFN-γ treatment causes cell shape changes, S100B redistribution, and downregulation of S100B mRNA. Exogenous nanomolar-to-micromolar S100B increases IFN-γ-induced iNOS mRNA expression and NO secretion in microglia.\",\n      \"method\": \"Immunofluorescence, RT-PCR, Western blot, phagocytosis assay with live imaging, NO measurement\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods in single lab; functional NO induction assay with localization data\",\n      \"pmids\": [\"11180510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"S100B promotes glioma growth in vivo by chemoattracting myeloid-derived macrophages/tumor-associated macrophages (TAM). S100B expression induced RAGE in vivo, but RAGE ablation did not significantly inhibit TAM infiltration, indicating RAGE-independent mechanisms. S100B upregulated CCL2 chemokine in high-S100B tumors, and CCL2 correlated with S100B expression in human glioma datasets.\",\n      \"method\": \"Stable transfection of GL261 glioma cells (S100B overexpression and knockdown), intracranial tumor implantation, RAGE knockout mice, chemokine analysis, TCGA database correlation\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic model with defined mechanism (CCL2 upregulation); single lab with bioinformatic support\",\n      \"pmids\": [\"23719262\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"S100B upregulates TNF-α and M1 macrophage markers in macrophages via RAGE; TNF-α reciprocally augments S100B secretion from adipocytes. Silencing S100B or RAGE neutralization significantly ameliorated TNF-α hypersecretion from macrophages stimulated with adipocyte conditioned media, establishing a paracrine loop between adipocytes (S100B secretion) and macrophages (RAGE-mediated activation).\",\n      \"method\": \"siRNA knockdown of S100B, RAGE-neutralizing antibody, conditioned media transfer, co-culture, ELISA\",\n      \"journal\": \"Obesity (Silver Spring, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic loop established by siRNA and antibody blockade; single lab, in vitro cell culture model\",\n      \"pmids\": [\"23804363\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"S100B upregulates IL-1β and CCL22 in macrophages (RAW264.7 and primary bone marrow-derived). In the Experimental Autoimmune Uveoretinitis model, S100B deletion in mice resulted in significantly reduced disease severity, reduced macrophage infiltration, and reduction of CCL22 and IL-1β in retinas, establishing a role for S100B in promoting macrophage-dependent retinal inflammation.\",\n      \"method\": \"PCR array, real-time PCR, flow cytometry, ELISA, S100B knockout mouse model, EAU histological grading\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro mechanistic data confirmed in S100B KO in vivo model; single lab with multiple readouts\",\n      \"pmids\": [\"26204512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"S100B impairs oligodendrocyte differentiation (OPC to mature MBP+ OL transition and morphological maturation) and myelination at micromolar concentrations. These effects were abolished by the RAGE antagonist FPS-ZM1, establishing that elevated S100B acts through the S100B-RAGE axis to impair oligodendrogenesis. In organotypic cerebellar slices, elevated S100B also impaired myelination, compromised neuronal/synaptic integrity, induced astrogliosis, NF-κB activation, and inflammation.\",\n      \"method\": \"Primary OL cultures, organotypic cerebellar slice cultures, RAGE antagonist (FPS-ZM1) rescue, immunofluorescence, Western blot\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological rescue with RAGE antagonist establishes mechanism; two culture models; single lab\",\n      \"pmids\": [\"29126910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"S100B promotes microglia M1 polarization with enhanced migration and inhibits M2 polarization. NF-κB is essential for S100B-mediated control of microglia M1/M2 polarization and migration. In vivo, S100B aggravated cerebral ischemia (MCAO model) and exacerbated microglia M1 polarization and migration.\",\n      \"method\": \"Real-time PCR, NF-κB pathway inhibition, migration assay, MCAO mouse model, S100B treatment in vivo\",\n      \"journal\": \"Inflammation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway inhibitor (NF-κB) mechanistic data confirmed in in vivo MCAO model; single lab\",\n      \"pmids\": [\"30229393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Strain injury to neuronal-glial co-cultures causes immediate release of S100B; adding exogenous S100B (10–100 nM) at 15 seconds, 6 hours, or 24 hours post-injury reduced delayed neuronal death at 48 hours, demonstrating a direct neuroprotective role of S100B after traumatic injury.\",\n      \"method\": \"In vitro stretch injury model (Silastic membrane), exogenous S100B treatment at multiple time points, propidium iodide neuronal death assay\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro traumatic injury model with multiple time-point rescue; single lab, single method\",\n      \"pmids\": [\"15584905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"S100beta-induced apoptosis in human neuronal precursor NT2/D1 cells is regulated by Bcl-2: S100beta treatment down-regulated Bcl-2 protein; bcl-2 gene transfer elevated Bcl-2 and repressed S100beta-mediated cell death; antisense bcl-2 knockdown in differentiated (retinoic acid-treated, Bcl-2-high) NT2 cells increased susceptibility to S100beta-induced apoptosis.\",\n      \"method\": \"bcl-2 gene transfer, antisense oligonucleotide knockdown, retinoic acid differentiation, cell death assays\",\n      \"journal\": \"Brain research. Molecular brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function of Bcl-2 with functional apoptosis readout; single lab\",\n      \"pmids\": [\"10381557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Pentamidine (an S100B inhibitor) disrupts S100B-wtp53 interaction in colon cancer biopsies, reducing S100B's ability to activate RAGE/phospho-p38 MAPK/NF-κB signaling, and restores wtp53 pro-apoptotic control (reduces iNOS, VEGF, IL-6 upregulation and rescues Bax). Niosomal pentamidine delivery (PENVE) was required for tissue penetration.\",\n      \"method\": \"Human biopsy cultures, immunoblot, EMSA, ELISA, biochemical assays for S100B-wtp53 interaction and downstream signaling\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic dissection in human tissue biopsies with multiple assays; single lab\",\n      \"pmids\": [\"32022398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"S100B knockdown in melanocytes increased apoptosis through inhibition of PI3K/AKT, NF-κB, and ERK activation, suggesting intracellular S100B protects melanocytes from chemically induced cytotoxicity. No RAGE expression was detected in melanocytes and CD166/ALCAM showed no significant function in melanocyte survival, pointing to intracellular (rather than RAGE-mediated) S100B function in this cell type.\",\n      \"method\": \"S100B siRNA knockdown, Western blot for PI3K/AKT, NF-κB, ERK signaling, flow cytometry, LDH assay\",\n      \"journal\": \"Experimental dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA with pathway analysis; single lab; negative RAGE finding mechanistically informative\",\n      \"pmids\": [\"24451020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In mesangial cells, HG-induced Steap4 protein expression was dependent on S100B; protein-protein interaction between Steap4 and S100B was confirmed by mass spectrometry of immunoprecipitated S100B. S100B-induced Steap4 gene transcription is mediated through a STAT3 site in the Steap4 promoter (via JNK, PI3K, and JAK/STAT3 pathways). Steap4 overexpression attenuates S100B-induced collagen IV, fibronectin, COX-2, and TGF-β expression.\",\n      \"method\": \"Co-immunoprecipitation/mass spectrometry, Steap4 promoter mutation analysis, kinase inhibitors (SP600125, LY294002, AG490), Steap4 overexpression, streptozotocin diabetic mouse model\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS-confirmed protein interaction, promoter mutation, in vivo validation; single lab\",\n      \"pmids\": [\"25817898\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"S100B is a Ca2+-binding EF-hand homodimer (capable of forming higher-order tetramers/octamers) that functions both intracellularly—interacting with targets including p53, phosphoglucomutase, intermediate filaments, microtubules, and annexins in a Ca2+-dependent manner to regulate cell survival, proliferation, and cytoskeletal dynamics—and extracellularly by engaging RAGE (with tetrameric S100B binding RAGE at higher affinity than dimers) to activate downstream pathways including NF-κB, ERK1/2, Cdc42-Rac1-JNK, and Ras-Rac1, triggering iNOS/NO production, COX-2 upregulation, macrophage polarization, and context-dependent pro- or anti-apoptotic outcomes; S100B also suppresses Aβ42 aggregation in a Ca2+-dependent manner, inhibits p53 activity in melanoma to block apoptosis, promotes sympathetic innervation of thermogenic adipose tissue as a calsyntenin 3β-dependent secreted neurotropic factor, and its transcription is regulated by SOX10 (in Schwann cells), the SOX trio (in chondrocytes), alpha1-adrenergic/PKC signaling (in cardiomyocytes), and YAP/TAZ-PRDM16-C/EBPβ (in adipocytes).\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"S100B is a Ca2+-binding EF-hand protein that operates as a dual-compartment signaling molecule, acting intracellularly to engage target proteins and extracellularly as a secreted ligand for the RAGE receptor [#0, #3]. Structurally it assembles beyond the homodimer into a tetrameric/octameric architecture, and the higher-order tetramer binds two RAGE molecules through the receptor V-domain with greater affinity than the dimer and drives stronger growth/survival signaling [#0]. Intracellularly, Ca2+-dependent binding partners include p53\\u2014where S100B sequesters wild-type p53 to suppress its phosphorylation, target-gene induction (p21, PIDD), and Fas-mediated apoptosis in melanoma, an interaction that can be pharmacologically disrupted to restore p53 pro-apoptotic control [#3, #24]\\u2014as well as the metabolic enzyme phosphoglucomutase (which S100B stimulates), annexin VI, and the vimentin intermediate-filament and microtubule networks, consistent with roles in cytoskeletal dynamics [#5, #6, #15]. Extracellular S100B signals through RAGE to activate NF-\\u03baB, ERK1/2, and parallel Cdc42-Rac1-JNK and Ras-Rac1 cascades, inducing COX-2, iNOS/NO production, and inflammatory mediators that drive microglial/macrophage M1 polarization and context-dependent neurotoxicity or neuroprotection [#0, #1, #4, #21, #22]. S100B also acts as a Ca2+-dependent chaperone that suppresses A\\u03b242 primary and secondary nucleation by binding monomers, oligomers, and fibrils, protecting cells from amyloid toxicity [#2]. As a secreted neurotrophic factor lacking a signal peptide, S100B is exported via calsyntenin 3\\u03b2 from thermogenic adipocytes to promote sympathetic innervation of adipose tissue [#11]. Its transcription is cell-type-specifically controlled by SOX10 in Schwann cells (where S100B supports myelination), the SOX9/SOX5/SOX6 trio in chondrocytes (where it restrains hypertrophic differentiation), alpha1-adrenergic/PKC signaling in cardiomyocytes (where it serves as a negative-feedback brake on hypertrophy), and a YAP/TAZ-PRDM16-C/EBP\\u03b2 axis in adipocytes [#7, #8, #12, #13, #14].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established that S100B dosage in vivo drives glial and neuronal remodeling, framing it as an active modulator of brain tissue architecture rather than a passive marker.\",\n      \"evidence\": \"S100B transgenic mice with 2- and 7-fold elevation, with quantitative glial/neuronal markers and hippocampal histology\",\n      \"pmids\": [\"8202493\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not distinguish intracellular versus secreted S100B effects\", \"Mechanism linking S100B to astrocytosis/axonal sprouting not defined\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Identified the first intracellular Ca2+-dependent enzyme target, showing S100B is a regulator of metabolic enzyme activity and that S100 paralogs can have opposite functional effects.\",\n      \"evidence\": \"Reciprocal affinity chromatography, gel overlay, and phosphoglucomutase enzyme activity assay\",\n      \"pmids\": [\"8894274\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro only; cellular relevance not tested\", \"Binding interface on S100B not mapped\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrated that extracellular S100B is neurotoxic through an astrocyte iNOS/NO intermediary, defining a non-cell-autonomous toxicity pathway.\",\n      \"evidence\": \"Astrocyte-neuron co-culture with NOS-inhibitor rescue and multiple cell-death readouts\",\n      \"pmids\": [\"9375660\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating S100B uptake/signaling not identified in this study\", \"Concentration threshold for toxic versus trophic effect not resolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Linked S100B to the cytoskeleton and apoptotic machinery, showing intracellular association with vimentin/microtubule networks and Bcl-2-dependent control of S100B-induced death.\",\n      \"evidence\": \"Immunogold EM with colchicine perturbation in myoblasts; bcl-2 gain/loss-of-function with apoptosis assays in neuronal precursors\",\n      \"pmids\": [\"10326676\", \"10381557\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical binding to filaments not confirmed in localization study\", \"How S100B engages the Bcl-2 axis mechanistically not defined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Resolved how S100B transcription is induced in the heart, establishing it as an alpha1A-adrenergic/PKC-driven negative-feedback brake on cardiomyocyte hypertrophy.\",\n      \"evidence\": \"Promoter deletion/luciferase analysis with adrenergic agonists/antagonists in cardiac myocytes; transgenic and forced-expression studies\",\n      \"pmids\": [\"12388300\", \"9677434\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the anti-hypertrophic effect is intracellular or RAGE-mediated unresolved at this stage\", \"TEF-1/RTEF-1 regulatory logic not connected to downstream effectors\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Dissected the extracellular S100B-RAGE signaling branch, showing it activates two parallel cascades (Cdc42-Rac1-JNK and Ras-Rac1-NF-\\u03baB) to induce COX-2 in microglia.\",\n      \"evidence\": \"Microglial culture with RAGE-dependent and pathway-specific inhibitor studies, Western blot and reporter assays\",\n      \"pmids\": [\"17023559\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Not independently replicated\", \"Relative contribution of each cascade to inflammatory output not quantified\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Provided the structural basis for ligand potency, showing S100B forms an octamer/tetramer that binds RAGE at higher affinity than the dimer and triggers stronger growth signaling.\",\n      \"evidence\": \"X-ray crystallography, analytical ultracentrifugation, and cell growth/survival assays\",\n      \"pmids\": [\"17660747\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of higher-order oligomers not established\", \"Downstream signaling differences between oligomeric states not mapped\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined a key intracellular oncogenic mechanism: S100B binds and suppresses p53 to block apoptosis in melanoma, and a RAGE/ERK1/p53 extracellular branch drives apoptosis in cardiomyocytes.\",\n      \"evidence\": \"siRNA, gain-of-function, and pifithrin-alpha rescue in melanoma cells; S100B knockout mouse with post-MI phenotyping and signaling readouts\",\n      \"pmids\": [\"20587415\", \"20204434\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural detail of the S100B-p53 interface not resolved here\", \"Why the same protein is anti-apoptotic intracellularly yet pro-apoptotic via RAGE is unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established cell-type-specific transcriptional control by SOX factors, with SOX10 driving S100B in Schwann cells to support myelination and restrain proliferation.\",\n      \"evidence\": \"SOX10 overexpression/knockdown, promoter SOX-motif mapping, and DRG myelination co-culture; SOX trio ChIP/EMSA in chondrocytes\",\n      \"pmids\": [\"25536222\", \"17396138\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream effectors of S100B in myelination/chondrocyte differentiation not defined\", \"Whether S100B acts intra- or extracellularly in these contexts not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Revealed a Ca2+-dependent chaperone function: S100B suppresses A\\u03b242 primary and secondary nucleation by binding monomers, oligomers, and fibrils, protecting cells from amyloid toxicity.\",\n      \"evidence\": \"NMR mapping of the interaction site, thioflavin-T aggregation kinetics, and cell viability assays\",\n      \"pmids\": [\"29963623\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo protective relevance in amyloid pathology not tested\", \"Whether the chaperone role competes with RAGE-driven inflammation in situ unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified the mechanism of S100B secretion and its trophic action, showing calsyntenin 3\\u03b2 drives ER localization/secretion of signal-peptide-lacking S100B to promote sympathetic innervation of fat.\",\n      \"evidence\": \"Adipocyte loss/gain-of-function with genetic epistasis (KO phenocopy plus rescue) and in vitro neurite outgrowth assay\",\n      \"pmids\": [\"31043739\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating S100B's neurotrophic effect on sympathetic neurons not identified\", \"Unconventional secretion route mechanistics beyond calsyntenin 3\\u03b2 dependence not detailed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Resolved upstream transcriptional gating in adipocytes, showing YAP/TAZ repress S100B by competing with C/EBP\\u03b2 for PRDM16, with adrenergic signaling releasing repression to permit beige-fat innervation.\",\n      \"evidence\": \"Adipocyte Yap/Taz knockout, AAV-S100B rescue, co-IP of YAP/TAZ-PRDM16-C/EBP\\u03b2, and transcriptional reporters\",\n      \"pmids\": [\"37925548\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How adrenergic phosphorylation of YAP/TAZ is integrated with other S100B promoters not connected across tissues\", \"Quantitative contribution to systemic thermogenesis not addressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single Ca2+-binding protein is partitioned between opposing intracellular (pro-survival, p53-suppressing, chaperone) and extracellular (RAGE-driven, often pro-inflammatory/cytotoxic) functions across cell types and concentrations remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking oligomeric state, concentration, and secretion to functional outcome\", \"RAGE-independent extracellular mechanisms (e.g., CCL2 in glioma) incompletely mapped\", \"In vivo balance of neurotoxic versus neuroprotective S100B not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 11]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 5, 24]},\n      {\"term_id\": \"GO:0044183\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [6, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [15, 16]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [15]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [15]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 11, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 18, 19, 21]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 4, 9]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [3, 9, 23]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [7, 12, 13, 14]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [11, 13, 14]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"RAGE\", \"TP53\", \"PGM1\", \"ANXA6\", \"CLSTN3\", \"PRDM16\", \"STEAP4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}